Skip to content
Boehringer Ingelheim
-
Boehringer Ingelheim inks USD500M immunology deal with Sitryx to target autoimmune disease
Sitryx stands to receive development, regulatory, and commercialization milestone payments exceeding USD 500 million, alongside tiered royalties on future sales if any drug from the partnership reaches the market.
-
Boehringer Ingelheim appoints Meenal Gauri as Managing Director for India region
She will oversee the pharmaceutical company’s operations across India, Bangladesh, Nepal, Sri Lanka, and Maldives while joining the Board of Boehringer Ingelheim India.